The present invention relates to a method for quantifying Aβ in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological Aβ accumulation occur. Through cut-off values of measured values measured by the method for quantifying Aβ according to the present invention, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of Aβ in the brain occurs, and it is possible to predict progression to AD.
METHOD FOR CLINICALLY AND PATHOLOGICALLY MONITORING ALZHEIMER'S DISEASE THROUGH CONCENTRATION OF AMYLOIDBETA IN PLASMA